Privately-held US CAR-T company ImmPACT Bio has tasked Jonathan Benjamin with leading its clinical development strategy as the company’s chief medical officer.
Dr Benjamin has extensive leadership experience in both early and late-stage clinical research and development in biopharma, as well as complementary clinical practice expertise as a hematologist-oncologist to ImmPACT Bio.
"ImmPACT Bio is at the forefront of CAR T-cell research"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze